 |
25 Products |  |
0 Diseases | | 25 Products |
|
112 Trials |  |
13941 News |  |
| «12345678910111213...224225» |
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19. (Pubmed Central) - Jul 19, 2024
Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Top 20 Research Studies of 2023 for Primary Care Physicians. (Pubmed Central) - Jul 19, 2024
An observational study of people with acute COVID-19 in the Omicron phase showed that nirmatrelvir/ritonavir was effective in reducing hospitalizations and death...Dextromethorphan, honey, and inhaled ipratropium do not appear to be effective for acute cough...Mindfulness-based stress reduction is not inferior to escitalopram in adults with anxiety disorders...People labeled as having a penicillin allergy can complete an amoxicillin oral provocation challenge in the primary care office and, following a negative result, have this label removed...Nonprescription hearing aids can be effective without a fitting by an audiologist. We wrap this up with the top guidelines of the year as determined by POEM readers.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Retrospective data, Review, Journal: Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis. (Pubmed Central) - Jul 18, 2024
Early use of oral antiviral drugs may potentially protect against developing PCC in non-hospitalized patients with COVID-19. These findings support the standardized administration of oral antiviral drugs in patients during the acute phase of COVID-19 according to the guidelines.
- Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Resolution of Neuropathic Pain after Anti-Viral Treatment for COVID- A Case Report (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_800;
Anti-retroviral therapy (such as in treating HIV) has been known to causative in sensory neuropathy (4), and the role of oral acyclovir is not thought to be as robust in preventing post-herpetic neuralgia, as per a Cochrane review.(5)We conducted a literature search but could not find any data that Paxlovid was used to treat neuropathic pain. Most systematic reviews, and other studies including some case reports were focused on the treatment of herpes zoster, and herpes zoster ophthalmicus, with anti-viral therapies.
- | Journal: Longitudinal Outcomes of COVID-19 in Solid Organ Transplant Recipients from 2020 to 2023. (Pubmed Central) - Jul 17, 2024
The study concludes that COVID-19 severity decreased across different variants in SOTr. Lung transplantation was associated with worse outcomes and may benefit more from preventive and early therapeutic interventions.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Clinical, Journal: Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. (Pubmed Central) - Jul 17, 2024
P2/3
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.).
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. (Pubmed Central) - Jul 17, 2024
Complete vaccination (3 doses) should be prioritized in these immunocompromised patients. The identified risk factors may help to improve COVID-19 management to decrease the rate of severe disease, ICU admissions and mortality.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Low Prevalence of Nirmatrelvir-Ritonavir Resistance-Associated Mutations in SARS-CoV-2 Lineages From Botswana. (Pubmed Central) - Jul 17, 2024
Higher rates were observed in Delta VOCs compared to Omicron and Beta VOCs. As NTV/r use expands globally, continuous surveillance for drug-resistant variants is essential, given the RAMs identified in our study.
- TQB3909 / Sino Biopharm
First Report of BCL-2 Inhibitor TQB3909 in Pts with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) and Acute Myeloid Leukemia (AML): Data From a Phase 1 Study (Toledo Auditorium - Hall 3) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1778;
- | romlusevimab (BRII-198) / Brii Biosci, amubarvimab (BRII-196) / Brii Biosci
New trial: Effect of Amubarvimab/Romlusevimab (BRII-196/198) administration on prognosis in patients post SARS-CoV-2 infection: a follow-up cohort study (EUDRACT) - Jul 15, 2024
P=N/A, N=80, Not yet recruiting, Sponsor: The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Trial completion: A Multi-Center Single-Blind, Randomized, Controlled Trial Evaluating the SARS-CoV-2 Rebound rate after full-course treatment of JT001 (VV116) Compared to Paxlovid for the Early Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19) (EUDRACT) - Jul 15, 2024
P3, N=478, Completed, Sponsor: Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
As NTV/r use expands globally, continuous surveillance for drug-resistant variants is essential, given the RAMs identified in our study. Not yet recruiting --> Completed
- || Review, Journal: A review on the current approaches and perspectives of Covid-19 treatment. (Pubmed Central) - Jul 15, 2024
The article brief l y describes the current epidemiological situation regarding COVID-19 and the currently used vaccines. Moreover, the paper outlines currently used and researched potential drugs in the pharmacotherapy of this disease.
- || azvudine (FNC) / Granlen
Clinical, Observational data, Retrospective data, Review, Journal: Efficacy and Safety of Azvudine in Patients With COVID-19 in China: A Meta-Analysis of Observational Studies. (Pubmed Central) - Jul 12, 2024
FNC appears to be a safe and potentially effective treatment for COVID-19 in China, but further research with larger, high-quality studies is necessary to confirm these findings. Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are applicable worldwide.
- || Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Jcovden (COVID-19 vaccine (Ad26.COV2-S [recombinant])) / J&J
P1/2 data, Journal: Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial. (Pubmed Central) - Jul 11, 2024
P1/2
Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are applicable worldwide. A heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination induced booster-specific immune responses detectable up to 1
- | remdesivir / Generic mfg.
Journal: Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes. (Pubmed Central) - Jul 10, 2024
The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.
- || Olumiant (baricitinib) / Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: How international guidelines recommend treating children who have severe COVID-19 or risk disease progression. (Pubmed Central) - Jul 10, 2024
Cure and virus negativity were obtained in all these high-risk patients. The guidelines provide useful advice and a degree of consensus on specific drug treatment for children with severe COVID-19 or at risk of progression.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Simultaneous portal vein thrombosis and splenic vein thrombosis in a COVID-19 patient: A case report and review of literature. (Pubmed Central) - Jul 10, 2024
In our patient, prompt abdominal imaging led to early detection of thrombus, early treatment, and an excellent outcome. This case is unique in that it is the second known case within the literature of simultaneous PVT and splenic artery thrombosis in a COVID-19 patient.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Retrospective data, Journal: Oral antivirals for COVID-19 among patients with cancer. (Pubmed Central) - Jul 9, 2024
Acknowledging the small size of our sample as a limitation, we concluded that early antiviral treatment might be beneficial to immunocompromised individuals, particularly those with cancer, when infected with SARS-CoV-2. Larger-scale, well-stratified studies are needed in this patient population.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Tacrolimus Level Increase During Nirmatrelvir-Ritonavir Treatment. (Pubmed Central) - Jul 8, 2024
Larger-scale, well-stratified studies are needed in this patient population. No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal, Combination therapy: Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm. (Pubmed Central) - Jul 8, 2024
No abstract available No abstract available
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations. (Pubmed Central) - Jul 8, 2024
We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.
- Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm
Immunogenicity, clinical efficacy, and safety of Sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: A prospective cohort study (Posters) - Jul 7, 2024 - Abstract #ECTRIMS2024ECTRIMS_248;
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus. (Pubmed Central) - Jul 4, 2024
Lastly, it highlights the indispensable role of pharmacist involvement in clinical decision-making and close monitoring in complex clinical scenarios. Although our findings are based on a single case, they align with current knowledge and suggest the potential of individualized combination therapy in managing challenging COVID-19 cases in immunocompromised patients.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Safety and Efficacy of Paxlovid in Pediatric Intensive Care Unit Patients with COVID-19. (Pubmed Central) - Jul 3, 2024
Although our findings are based on a single case, they align with current knowledge and suggest the potential of individualized combination therapy in managing challenging COVID-19 cases in immunocompromised patients. The application of paxlovid in critically ill pediatric patients with COVID-19 can effectively control symptoms and promote virus clearance, demonstrating efficacy and a relatively low-risk profile.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Associations between COVID-19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS-CoV-2 variants. (Pubmed Central) - Jul 2, 2024
Despite advancements in treatment and vaccinations, disparities in adverse COVID-19 outcomes persist between urban and rural communities. The effectiveness of some therapeutic agents appears to vary based on rurality, suggesting a nuanced relationship between treatment and geographic location while highlighting the need for targeted rural health care strategies.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: COVID-19 clinical rebound after treatment with nirmatrelvir/ritonavir. (Pubmed Central) - Jul 1, 2024
Only one patient (6.25%) was hospitalized after COVID-19 rebound. COVID-19 clinical rebound after treatment with NM/r is mild with favorable outcomes and more common than previously reported from real-world clinical care studies.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Observational data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative. (Pubmed Central) - Jul 1, 2024
Overall, high-risk, nonhospitalized adult patients with COVID-19 who were treated with Paxlovid within 5 days of SARS-CoV-2 infection had a lower risk of Long COVID and all-cause hospitalization or death in the post-acute period. However, Long COVID risk reduction with Paxlovid was not observed in low-risk patients.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections. (Pubmed Central) - Jul 1, 2024
Studies in golden Syrian hamsters demonstrated efficient transmission to contact animals. This study documents the isolation of SARS-CoV-2 carrying resistance mutations to both nirmatrelvir and remdesivir from a patient and demonstrates its transmissibility in vivo .
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir-ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial. (Pubmed Central) - Jun 29, 2024
Most adverse events were mild in both groups. In summary, SHG was superior to nirmatrelvir-ritonavir in shortening the time to sustained clinical recovery in participants with mild-to-moderate COVID-19, despite a lower virus clearance rate observed after 5
- | Imbruvica (ibrutinib) / AbbVie, J&J
Journal: A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments. (Pubmed Central) - Jun 29, 2024
CONCLUSIONS This is an emblematic case of correlation between persistent SARS-CoV-2 infection and immunosuppression status in hematological hosts. In these patients, the viral load remains high, favoring the evolution of the virus, and the immunodeficiency makes it difficult to identify the appropriate therapeutic approach.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Proline Analogues. (Pubmed Central) - Jun 28, 2024
We overview (1) the occurrence of proline analogues in nature and their chemical synthesis, (2) physicochemical properties including ring conformation and cis/trans amide isomerization, (3) use in commercial drugs such as nirmatrelvir recently approved against COVID-19, (4) peptide and protein synthesis involving proline analogues, (5) specific opportunities created in peptide engineering, and (6) cases of protein engineering with the analogues. The review aims to provide a summary to anyone interested in using proline analogues in systems ranging from specific biochemical setups to complex biological systems.
- || Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups. (Pubmed Central) - Jun 28, 2024
The consensus antiviral treatment is combination therapy using Nirmatrelvir and Ritonavir, and the consensus for pre-exposure prophylaxis is Tixagevimab and Cilgavimab combination. We hope the present paper raises awareness for the continuing presence of COVID and ways to lower the risks, especially for at-risk groups.
- | Covilo (BBIBP-CorV) / Wuhan Institute of Virology, Sinopharm, Zifivax (ZF2001) / Chinese Academy of Medical Sciences, Chongqing Zhifei
Journal: Proteomic and cellular characterization of Omicron breakthrough infections and a third homologous or heterologous boosting vaccination in a longitudinal cohort. (Pubmed Central) - Jun 27, 2024
Breakthrough infections can trigger more intensive inflammatory chemokine responses than vaccination. T-cell and innate immune activation have been shown to be closely related to enhanced antibody levels after vaccination and therefore might be potential targets for vaccine adjuvant design.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi
Journal: Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir. (Pubmed Central) - Jun 27, 2024
Using the surrogate virus, we previously selected hallmark mutations of SARS-CoV-2-Mpro, such as T21I, M49L, S144A, E166A/K/V and L167F. In the current study, we selected a pool of MERS-CoV-Mpro mutants, characterized the resistance and modelled the steric effect of catalytic site mutants S142G, S142R, S147Y and A171S.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal: Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients. (Pubmed Central) - Jun 27, 2024
Nirmatrelvir/r dosage was rarely adjusted to renal function. Dose adjustments and closer monitoring are needed due to the high risk of drug interactions.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment status: RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms (clinicaltrials.gov) - Jun 27, 2024
P2, N=900, Recruiting, Sponsor: Kanecia Obie Zimmerman
Dose adjustments and closer monitoring are needed due to the high risk of drug interactions. Enrolling by invitation --> Recruiting
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment status: RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (clinicaltrials.gov) - Jun 26, 2024
P2, N=900, Recruiting, Sponsor: Kanecia Obie Zimmerman
Enrolling by invitation --> Recruiting Enrolling by invitation --> Recruiting
- | Journal: The effect of calf subcutaneous fat thickness on patient satisfaction after calf contouring with botulinum toxin A. (Pubmed Central) - Jun 26, 2024
This study identified a U-shaped correlation between calf subcutaneous fat thickness and patient satisfaction rate after treatment. The authors' results provide a theoretical basis for BTXA treatment and suggest the importance of preprocedure conversations in GM hypertrophy treatment.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk. (Pubmed Central) - Jun 26, 2024
Although its use is recommended in lactating women, there are no previous studies on the transfer of nirmatrelvir into human milk. The study findings endorse the current approach of nirmatrelvir/ritonavir use in lactating women and encourage healthcare providers to consider prescribing this treatment irrespective of lactation status when indicated.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Oral antiviral utilisation among older adults with COVID-19 in primary care: A population-wide study during successive Omicron waves in Singapore. (Pubmed Central) - Jun 26, 2024
The study findings endorse the current approach of nirmatrelvir/ritonavir use in lactating women and encourage healthcare providers to consider prescribing this treatment irrespective of lactation status when indicated. No abstract available
- Perioperative Pain Medicine in Multi-specialty Anesthesiology Practice for Patients With Long COVID Pain Syndrome (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1229;
No abstract available Abstract is embargoed at this time.
- Perioperative Pain Medicine in Multi-specialty Anesthesiology Practice for Patients With Long COVID Pain Syndrome (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_922;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V. (Pubmed Central) - Jun 24, 2024
The mutation-induced conformational perturbations alter drug-protein local contact intensities and the electrostatic preorganization of the protein, affecting noncovalent binding affinity and the stability of key reaction states, respectively. Our findings inform the mechanisms of nirmatrelvir resistance and sensitivity, facilitating improved drug design and the detection of resistant strains.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Paxlovid (Pubmed Central) - Jun 20, 2024
Our findings inform the mechanisms of nirmatrelvir resistance and sensitivity, facilitating improved drug design and the detection of resistant strains. Paxlovid
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Preclinical, Journal: Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations. (Pubmed Central) - Jun 19, 2024
Together these results show that chronic deficiencies in neuronal function in SARS-CoV-2-infected mice are not directly linked to ongoing olfactory epithelium dysfunction. Rather, they bear similarity with neurodegenerative disease, the vulnerability of which is exacerbated by chronic inflammation.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Retrospective data, Journal: Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study. (Pubmed Central) - Jun 19, 2024
Our study may provide new insight that inpatients with severe or critical COVID-19 beyond five days of symptom onset benefit from Nmr/r. Future studies, particularly randomized controlled trials, are necessary to verify the above findings.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. (Pubmed Central) - Jun 17, 2024
However, nirmatrelvir showed a significant decrease in inhibiting the replication of mutant SARS-CoV-2 SRIPs carrying Mpro_E166V (EC50: > 20 ?M) and Mpro_Q189I (EC50: 13.2 ?M) compared to wild-type SRIPs (EC50: 0.06 ?M). Overall, this study identifies four GL derivatives as promising lead compounds for developing treatments against various SARS-CoV-2 strains, including Omicron, and nirmatrelvir-resistant variants.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19? (Pubmed Central) - Jun 17, 2024
Nasal and inhaled treatment with soluble ACE2 receptors has abrogated severe disease in animal models of COVID-19. There is an urgent need for clinical trials of this new class of antiviral therapeutics, which could complement vaccines and Paxlovid.
- || Review, Journal: Efficacy, Effectiveness, and Safety of COVID-19 Vaccine Compared to Placebo in Preventing COVID-19 Infection among 12-17 Years Old: A Systematic Review. (Pubmed Central) - Jun 17, 2024
Different countries should consider whether to vaccinate healthy adolescent without comprising the other recommended immunization and health priorities that are crucial for this age group. Other factors including cost-effectiveness of vaccination and disease burden should be accounted.
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China. (Pubmed Central) - Jun 16, 2024
Multivariate analysis indicated that the absence of Paxlovid treatment was a distinct risk factor for hospitalizations lasting over 7?days (OR: 4.983, 95% CI: 3.828-6.486, p?<?0.001) and 14?days (OR: 2.940, 95% CI: 2.402-3.597, p?<?0.001). Amid the Omicron outbreak, Paxlovid has proven to be a safe and effective treatment for reducing hospitalization durations for patients with mild to moderate COVID-19.